Glaucoma refers to a group of chronic, progressive eye diseases caused primarily by elevated intraocular pressure (IOP) resulting from the blockage or decreased drainage of the aqueous humor…
Improvements in patient access to novel treatments for chronic obstructive pulmonary disease (COPD) in Brazil and Mexico are largely dependent on the expansion of drug coverage by local authorities…
This report is a series of four post-launch reports that evaluates the trial and usage of XELJANZ (tofacitinib) among rheumatologists for the treatment of rheumatoid arthritis (RA). LaunchTrends®…
Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma. The first-generation protease inhibitors were a major advancement in the…
TreatmentTrends: Dry/Wet Age-Related Macular Degeneration (US) is an annual syndicated report series that offers a snapshot of dry and wet age-related macular degeneration (AMD) market dynamics and…
Uveitis, caused by inflammation of the eye’s uvea, presents as decreased or blurry vision, ocular ache, eye redness, photophobia, and/or floaters. Uveitis cases can vary depending on etiology,…
Gastrointestinal stromal tumors (GISTs) are rare cancers that belong to a group of cancers known as soft tissue sarcomas, which develop in supporting and connective tissues. GISTs account for…
Currently available therapies for the treatment of Ankylosing Spondylitis (AS) target primarily the signs and symptoms of the disease; scant data exist demonstrating an impact on structural…
LaunchTrends®: Xofigo is a series of three post-launch syndicated reports designed to track physician perception, uptake, and the competitive environment of newly launched Xofigo (Algeta/Bayer…
A syndicated report that will provide information on various hyperphosphatemia market dynamics. It provides insight into practice patterns, attitudes and perceptions, and current and projected…
Several newly approved agents for asthma together with others seeking approval are expanding the range of therapeutic options for this disease in Brazil and Mexico. Drugs such as the inhaled…
With more than 32 million people in the United States diagnosed with osteoarthritis (OA), it is the most common type of arthritis and a leading cause of disability. Among the symptoms…
High unmet need exists for severe, refractory asthma patients, for whom Genentech/Novartis’s Xolair is currently the only therapeutic option. Together with a number of newly approved agents for…
The syndicated ChartTrends: Multiple Sclerosis (US) report allows clients to better understand the actual treatment of multiple sclerosis (MS) with disease-modifying therapies (DMTs) through…
Do Physicians Have High Hopes for LDL-Lowering Therapies in Cardiovascular Outcomes? As one of the most prevalent diseases in the major pharmaceutical markets, dyslipidemia represents a compelling…